ClinicalTrials.gg
RecruitingNCT04957355NMESUpdated May 22, 2026

Effect of NMES on Balance and Fall Risk in Chronic Stroke

An interventional study of Neuromuscular electrical stimulation (NMES) or Functional electrical stimulation (FES) in Chronic Stroke, sponsored by University of Illinois at Chicago. Recruiting at 1 site in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by University of Illinois at Chicago · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Stroke by University of Illinois at Chicago — 7 open to participants now, 9 under way, none of them phase 3. Stroke · University of Illinois at Chicago.

Planned enrollment
13th of 15
20 · median 46
Started
2021
the only one that year
No phase
14 of 16
7 open now
Registered
8th of 16
by date

Among the 16 studies in Stroke by University of Illinois at Chicago, this one is the 13th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2021, is one of 14 with no phase, and was the 8th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

7 of the 16 studies in Stroke by University of Illinois at Chicago are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Stroke by University of Illinois at Chicago, or all of them as a file.
02

Study summary

The aim of this study is to describe the effect of neuromuscular electrical stimulation (NMES) in the form of functional electrical stimulation (FES) applied to different lower limb muscles on reactive balance and gait performance in stroke participants.

Methods: Twenty individuals with chronic stroke will be asked to perform an experimental protocol that includes a postural disturbance in the form of a slip- or trip-like perturbation and a standardized walking test in both laboratory and outdoor environments with and without FES applied to different lower limb muscles of the paretic leg. FES will be applied using an advanced software that is able to synchronize muscle activation with the time of perturbation onset and according to the phases of gait.

This project design aims to examine whether a specific pattern of lower limb muscle stimulation could improve the kinematic and behavioral responses during reactive balance following slip- and trip-like perturbations. Additionally, the project aims to see if the kinematic and spatio-temporal gait parameters can be modified during a standardized walking test under different sensory and environmental conditions.

Read the detailed description

Functional impairment after a stroke often includes slowed gait velocity and increased fall risk attributed to foot drop (the inability to dorsiflex the ankle during the swing phase of gait) and lower limb muscle weakness. Damage in the motor cortex or corticospinal tract often results in significant, persistent distal muscle weakness, including the sensorimotor control of the ankle joint, typically because of a combination of weakness of the agonist ankle dorsiflexor muscles and spasticity of the antagonist plantar flexor muscle. This results in slower and abnormal gait which leads to gait compensation strategies such as hip hitching, excess circumduction during gait, reduced foot clearance, and high energy expenditure, all of which are factors which could increase the risk of falls in individuals with stroke.

Functional electrical stimulation (FES) corresponds to the application of an electric field across the motor neurons of a muscle to induce an artificial, involuntary contraction to perform a functional movement. Numerous benefits of FES have been reported throughout literature such as increased muscle mass, increased bone mineral density, and improved cardiovascular parameters, among others. Previous studies in which authors assessed the effect of FES on individuals with stroke have demonstrated that the common peroneal nerve stimulates the tibialis anterior muscle to produce foot dorsiflexion during the swing phase of the gait cycle and reduces foot drop by facilitating increased voluntary muscle activity, which together improves the quality and symmetry of gait. Additionally, others studies showed that FES improves walking speed and energy expenditure in individuals with stroke.

In the last years, FES systems have been used as neuroprosthetic devices in rehabilitative interventions such as gait training. Stimulator triggers, implemented to control stimulation delivery, range from open- to closed-loop controllers.12 Finite-state controllers trigger stimulators when specific conditions are met and utilize preset sequences of stimulation. Thus, wearable sensors provide the necessary input to differentiate gait phases during walking and trigger stimulation to specific muscles.13 This technology has been largely used to improve gait parameters in stroke participants, however, it has not been well described how this technology could help stroke participants during the loss of balance or during reactive balance.

On the other hand, the literature suggests that a direct transcortical loop does not trigger the initial phase of postural responses to external perturbations, but it seems likely that the cerebral cortex becomes involved in the later phases of the reactive response.14 Thus, given that postural response lasts for many hundreds of milliseconds, it may be that the brainstem or spinal cord circuits initiate a response, and then the response subsequently becomes modified by cortical circuits during its later phases.15 In this context, the effect of peripheral stimulation to the muscles involved in the reactive response to an unexpected external perturbation on recovery performance has not yet been described.

This project aims to describe whether a specific pattern of lower limb muscle stimulation could modify the recovery response after an unexpected perturbation in the form of a slip and/or trip in individuals with stroke. Also, this project aims to examine if a specific pattern of lower limb muscle stimulation provided by FES can modify kinematic and spatio-temporal gait parameters during a standardized walking test under different sensory conditions.

03

Conditions studied

  • Chronic Stroke

Browse trials for

Keywords

  • functional electrical stimulation
  • neuromuscular electrical stimulation
  • walk-training
  • treadmill training
  • reactive balance
  • perturbation
  • falls
  • fall prevention
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age group: 18-90 years.

  1. Presence of hemiparesis.
  2. Onset of stroke (> 6 months).
  3. Ability to walk independently with or without an assistive device for at least 300 ft.
  4. Can understand and communicate in English.
  5. Cognitively and behaviorally capable of complying with the regimen ( > 25/30).

Exclusion criteria

Exclusion Criteria:

Subjects will not proceed with the test if any of the following occurs at baseline measurement: 1) HR > 85% of age-predicted maximal heart rate (HRmax) (HRmax = 220 - age), 2) systolic blood pressure (SBP) > 165 mmHg and/or diastolic blood pressure (DBP) > 110 mmHg during rest, or 3) oxygen saturation (measured by pulse oximeter) \< 95% during rest.

  1. Body weight more than 250 lbs.
  2. Any neurological condition other than stroke.
  3. Any cardiopulmonary, musculoskeletal, or systemic diagnosis.
  4. Recent major surgery (\< 6 months) or hospitalization (\< 3 months).
  5. Deep venous thrombosis.
  6. Antecedent of cancer.
  7. Peripheral nerve injury or neuropathy in the affected limb with motor disability.
  8. Spasticity (Ashworth scale > 2).
  9. Uncontrolled high blood pressure/angina.
  10. Skin condition not tolerant with FES therapy.
  11. Uncontrolled seizure disorder.
  12. Botox treatment within the last 5 months.
  13. History of epilepsy.
  14. Pacemaker users.

Excluded or Vulnerable Populations Non-English speaking populations will be excluded as the consent procedures and instructions will be in English.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Effect of functional electrical stimulation on reactive balance and laboratory falls

    All individuals will be assigned to the experimental group and will undergo the testing and training procedure across two separate sessions. During the first session, the participants will go through the complete initial screening process. If eligible for the study, the participants will perform the experimental training protocols during the second session. Experimental Protocol The quadriceps, hamstrings, tibialis anterior, gastrocnemius, and the trunk muscle group on the stroke-affected side (weaker side) will be stimulated according to the participant's comfort and tolerance. The range of the intensity allowed by the device is 0-50milliamperes (mA). The frequency of the electrical stimulation device ranges from 1-60Hz.

    Device: Neuromuscular electrical stimulation (NMES) or Functional electrical stimulation (FES)

Interventions

  • DeviceNeuromuscular electrical stimulation (NMES) or Functional electrical stimulation (FES)

    Stance and Walk-Perturbation Training Protocol ActiveStep and Surefooted Protocol: Perturbation training protocol with and without FES Participants will be asked to perform a postural disturbance protocol in the stance position and walk in the form of 7 slips and 7 trips with two retention trials after the training using the ActiveStep treadmill system while fitted in a safety harness. All perturbations will be delivered at each participant's comfortable walking speed. Similar slip and trip training in walking will be conducted on the surefooted platform with and without FES. Gait Training Protocol and Surefooted protocol Participants will be asked to perform a 10m walking test (walking for a distance of 45 feet) in a laboratory environment six times (three times with and without FES) and in an outdoor environment located in the parking lot of the Applied Health Science building (1919 W. Taylor St., Chicago, IL)

06

What researchers measure

Primary outcomes

  1. Laboratory Falls

    The outcome of a perturbation trial is dichotomous with #1 being a fall, which is assigned if the force detected by the load-cell exceeded 30% of the participant's body weight after perturbation or if the researcher assists the participant to attain a standing position following perturbation. Otherwise, the outcome is regarded as a non-fall (#0). Laboratory falls are reported in percentage (%), defined as the number of falls experienced during perturbation trials related to the total number of perturbation trials.

    Time frame: Baseline (1st Novel slip/trip, Session 2, Week 1)

Secondary outcomes

  1. Reactive (post-slip) Stability

    Post-slip (reactive) stability is calculated from the COM state (position and velocity) and computed at the instance of the first compensatory limb touchdown post-slipping. Values \< 0 indicated a greater possibility of experiencing backward loss of balance and vice versa for values \> 0.

    Time frame: Baseline (1st Novel slip/trip, Session 2, Week 1)

  2. Pre-slip Stability

    Pre-slip stability is calculated from the COM state (its position and velocity) and computed at the instance of slipping limb touchdown (before the perturbation onset).

    Time frame: Baseline (1st Novel slip/trip, Session 2, Week 1)

  3. Vertical limb support

    Vertical limb support will be quantified by the hip height i.e., the vertical distance between the midpoint of bilateral hips to the floor (Zhip), which is determined from the anterior-superior iliac spine markers and normalized by each participant's body height. The hip height will be assessed at the instance of post-slip compensatory limb touchdown, which indicates the instance of maximal hip descent following perturbation. Higher hip height values indicate greater vertical limb support.

    Time frame: Baseline (1st Novel slip/trip, Session 2, Week 1)

  4. Compensatory step length

    The step length will be assessed as the distance from slipping heel to non-slipping heel at the instance of recovery touchdown. A more negative step length indicated a longer backward compensatory step and vice versa.

    Time frame: Baseline (Session 2, Week 1)

  5. Compensatory step initiation time

    The time taken for liftoff of the compensatory limb after the perturbation onset is termed as the compensatory step initiation time.

    Time frame: Baseline (Session 2, Week 1)

  6. Compensatory step execution time

    The time taken from liftoff of the compensatory limb to its first touchdown is termed as the compensatory step execution time.

    Time frame: Baseline (Session 2, Week 1)

  7. Number of compensatory steps

    Number of compensatory steps will be assessed as the number of steps required to regain balance following slip onset till the participants resume their regular gait pattern.

    Time frame: Baseline (Session 2, Week 1)

  8. Medio-Lateral excursion of center of mass

    The peak excursion of the COM perpendicular to the walking direction.

    Time frame: Baseline (1st Novel slip/trip, Session 2, Week 1)

  9. Center of mass excursion angle

    the deviation of the Center of mass relative to the sagittal plane

    Time frame: Baseline (1st Novel slip/trip, Session 2, Week 1)

  10. Gait speed

    Gait speed will be measured in meters per second (m/s) via the GaitRite assessment mat and via the three-dimensional inertial triaxial sensors. Higher gait speed indicates better walking performance.

    Time frame: Baseline (Session 2, Week 1)

  11. Walking cadence

    Cadence will be determined during walking performance with and without NMES via walking on the treadmill (activestep) and the GaitRite mat. Lower cadence indicate better performance.

    Time frame: Baseline (Session 2, Week 1)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Purohit R, Varas-Diaz G, Bhatt T. Functional electrical stimulation to enhance reactive balance among people with hemiparetic stroke. Exp Brain Res. 2024 Mar;242(3):559-570. doi: 10.1007/s00221-023-06729-z. Epub 2024 Jan 12. PubMed 38214733 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Aug 2027, 75 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 75 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2021
First posted
Jul 12, 2021
StartActual
May 15, 2021
Primary completionEst.
Aug 31, 2027
CompletionEst.
Nov 30, 2027
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04957355
Responsible party
Tanvi Bhatt (Associate Professor, University of Illinois at Chicago) — Principal investigator
First posted
Jul 12, 2021
Start date
May 15, 2021
Primary completion
Aug 31, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
May 22, 2026

Study contacts

Rudri M Purohit, MS,PT
Contact
rpuroh2@uic.edu
3124139772
Lakshmi Kannan, MS,PT
Contact
lkanna2@uic.edu
3124133175
Tanvi Bhatt, PhD
principal investigator · University of Illinois at Chicago

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion